MDxHealth (MDXH)
Molecular prostate-cancer tests for testing and treatment decisions.
Something off on this page? Send us feedback.
Offers molecular prostate-cancer tests, including Confirm mdx, GPS mdx and Exo mdx, to support testing and treatment decisions. It operates as one segment, with revenue primarily generated in the United States through tissue- and liquid-based testing.
Provides molecular diagnostics for prostate-cancer decision making. Its current menu includes Confirm mdx for men at risk of prostate cancer, GPS mdx for newly diagnosed men considering treatment or active surveillance, and Exo mdx, a liquid-based test.
Revenue is primarily generated in the United States, although the parent company is incorporated in Belgium. The business reports one segment and earns tissue-based and liquid-based testing revenue.
Operations depend on clinical-lab reimbursement, regulatory approvals and compliance, integration of acquired GPS and ExoDx assets, and creditor covenants. After a reimbursement-policy reversal, the company announced plans to discontinue Resolve UTI and close its Plano laboratory, concentrating on core prostate-cancer testing.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 21, 2026 | BTIG | Reiterate | Rating: —Target: $4 | Target: $2 |
| Aug 14, 2026 | Lake Street | Reiterate | Rating: —Target: — | Target: $3 |
| May 14, 2026 | BTIG | Reiterate | Rating: —Target: $15 | Target: $4 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $19.2M · Total debt $105.8M · Total assets $132.1M · Shareholders' equity −$30.4M
- Revenue
- $27.2M
- Operating income
- −$5.1M
- Net income
- −$11.5M
No dividends on record.
| Institutions | 32.30% | 16.59M ADS | |
|---|---|---|---|
| 26 holders · as of Jun 30, 2026 | |||
| Insiders | 6.22% | 3.19M ADS | |
| 2 holders · as of Apr 13, 2026 | |||
| Strategic holders | 12.54% | 6.44M ADS | |
| 1 holder · as of Jan 16, 2026 | |||
| Other | 48.94% | 25.14M ADS | |
| remainder | |||
51.36M ADS (1 ADS = 3 ordinary shares) as of Sep 10, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count is from the company's Dec 2021 annual report; nothing newer is on file here.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Bleichroeder LPInstitution | 14.36% | 7.38M ADS | as of Jun 30, 2026 |
Genomic Health, Inc.Strategic | 12.54% | 6.44M | filed Jan 16, 2026 |
AWM Investment Company, Inc.Institution | 9.49% | 4.88M | filed Feb 7, 2025 |
MVM Partners, LLCInstitution | 9.15% | 4.70M ADS | as of Jun 30, 2026 |
Laurence W. LyttonInsider | 6.16% | 3.16M | filed Nov 14, 2025 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 13, 2026 | MVM Partners, LLC | director | +2,202,643 | $0.4540 |
- Veracyte
Biopsy-based prostate genomic classification for treatment decisions
- Myriad Genetics
Localized-prostate genomic risk stratification and treatment planning
- OPKO Health
Blood-based risk assessment before a prostate-biopsy decision
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| MDxHealth | $0.6008 | +0.15% | $30.8M | — | — | 0.4 | −0.8% |
| Veracyte | $42.60 | −1.75% | $3.46B | 31.0 | 23.5 | 6.2 | +15.5% |
| Myriad Genetics | $4.07 | +1.12% | $379.7M | — | — | 0.5 | −10.5% |
| OPKO Health | $1.72 | −0.87% | $1.29B | — | — | 2.2 | +4.3% |
| Median | 31.0 | 23.5 | 2.2 | +4.3% |